Bendamustine Hydrochloride Case Study

1. A 54-year-old patient is seen by the physician in the outpatient clinic setting for CLL that is currently in remission. The patient's WBC counts, particularly lymphocytes remain within normal limits

He was given a prescription for Fexmid (cyclobenzaprine hydrochloride) 7.6 mg #90 1 tablet every 8 hours as needed to reduce muscle spasms, Voltaren XR (diclofenac sodium XR) 100 mg 1 tablet #60 1 tablet twice daily as needed for inflammation, and topical creams.

daily. She is also on metoprolol tartrate 25 mg half tablet b.i.d. She cannot tolerate ACE inhibitors or ARB secondary to angioedema in the past. The patient was started on metoprolol after an episode of ventricular tachycardia with ectopy for which she was hospitalized. She does see David Cunningham

Have other medications been tried and discontinued since last review? If yes, please list medications and response to them.

Per the Request for Authorization form dated 09/19/16, IW was prescribed with Naprosyn 500 mg 1 tablet three times daily #90, omeprazole 20 mg 1 capsule daily #30 and Elavil 25 mg a t bedtime #30.

The treatment of patients with mild disease consists of acid suppression (esomeprazole) and a short course of steroids (prednisolone). Those patients who have moderate to severe disease should be treated aggressively in the following way: acid suppression (esomeprazole), a longer course of steroids with prednisolone, and consideration of immunosuppressive therapy with azathioprine. Infliximab should be considered in refractory patients in order to prevent the complications of stricturing and fistula formation. Treatment with balloon dilatation of the stricture followed by injection of a long-acting steroid such as triamcinolone can also help to alleviate symptoms. Surgery may be required for severe, refractory symptoms, but it has a high morbidity

Other treatments that could be order are Clarithromycin 500mg twice daily for five days or Clarithromycin XL 1000 mg (Two 500 mg tablets) daily for five days (File, 2017).

3) Compared two drugs of interest. 4) Have similar groups, allocation concealment, baseline validity and reliability of measures in order to eliminate bias of studies 5) Have low risk of bias. 6) Patients that receive medication treatment within twelve months after diagnosis. The strength of evidence was graded as high, moderate, low or insufficient based on established guidelines on four criteria: a) Risk of bias b) Consistency c) Directness d) Precision

The trial had thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, that were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. The results showed that 26 patients completed the study, with three deaths and one lost to follow-up. Overall, 19 (73.07%) of the patients had improved or stabilized lung disease with the completion of the trial. After the 6-month follow-up period, 12 (54.5%) of the 22 patients showed improved or stabilized lung disease.

Pt is currently on citalopram 20 mg one-half tablet by mouth once daily. Citalopram is appropriate as first line therapy for treatment of major depression per APA Practice guidelines. Starting dose of citalopram is also appropriate as patient is elderly. Citalopram has no major drug interactions with pt’s current medications or current medical conditions. Pt reports tolerating it well and has been adherent to

Among the agents mentioned above thalidomide, bortezomib, lenalidomide, pomalidomide, carfilzomib, daratumumab, elotuzumab and panobinostat are the major drugs used in

Dosages of the drug vary from one extreme to another based upon the patients needs.

The preferred oral agent are Revlimid or Cytoxan. Thalidomide is not commonly used d/t excessive side effects.

If on the leaflet (which should ALWAYS be kept near the drugs) it says that a medical professional should be contacted if some reactions occur (i.e. bleeding) then follow the instructions. Some reactions may occur but no further medical help is required unless it becomes very bad (like the possible constipation with pain killers such as co codamol, paracetamol etc.)

They were five double blind, placebo controlled trials for Candesartan celexetil hydrochlorothiazide, which we're eight weeks to twelve weeks in duration. The combined study sample consisted of 3,037 hypertensive patients and dosage ranged from 2 to 32 mg Candesartan celexetil and from 6.25 to 25 mg hydrochlorothiazide administered once daily in several combinations (www.centerwatch.com).